Q1168. What biological drug regulations govern biological medical drug registrations?

Answered by the NYC Visa & Translation certified translation team

Biological drug registration in Thailand is governed by the Thai FDA under the Drug Act, with biologics (vaccines, monoclonal antibodies, cell and gene therapies) subject to the deepest technical review of any product category. The registration dossier: follows the ACTD format with the biologics-specific data — the quality section (the manufacturing process description, the characterisation studies, the comparability data) is the technical core and the hardest translation: the biotechnology terminology (cell lines, expression systems, purification steps, analytical methods) requires a translator with biopharmaceutical background, and the analytical data tables are transcribed with the methods and specifications exact; the nonclinical and clinical sections follow the standard dossier structure; and the manufacturing site evidence (the GMP certificates, the site master file) is legalised and translated. Rules that matter: the product's naming (the INN and the product name) must be consistent across the dossier; the stability data supporting the shelf life is numeric text with the storage conditions exact; and the cold chain requirements (critical for biologics) appear in the labeling and the distribution commitments. Points that matter: the registration timeline for biologics is long (commonly 1–2 years with the review rounds); the Thai FDA's questions during review require translated responses on deadline; and post-approval changes (variations) follow their own filing rules. Practice points: establish the biotech terminology glossary at the start and maintain it across the dossier and the review correspondence; and confirm the Thai FDA's current requirements for the specific product category before preparing the set.